Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2021 Jun 3;11:11740. doi: 10.1038/s41598-021-90819-x

Additional partial hepatectomy at the time of portal vein ligation accelerates the regeneration of the future liver remnant

Chuanfeng Hua 1,#, Weiwei Wei 2,#, Tianjiao Zhang 3, Fengming Xu 1, Olaf Dirsch 4, André Homeyer 5, Utz Settmacher 1, Uta Dahmen 1,✉
PMCID: PMC8175446  PMID: 34083554

Abstract

Portal vein ligation (PVL) has been adopted to induce hypertrophy of the future liver remnant (FLR) in patients with primarily irresectable liver tumor. However, regeneration of the FLR is not always sufficient to allow curative resection of the portally-deprived tumor-bearing liver lobe. We hypothesize that simultaneous hepatectomy (PHx) and PVL augments regeneration of the FLR and that the effect is related to the extent of the additional resection. Seventy-two Lewis rats were enrolled into 3 groups: 20%PVL + 70%PHx; 70%PVL + 20%PHx; 90%PVL. Animals were observed for 1, 2, 3 and 7 days postoperatively (n = 6/time point). Liver enzymes, caudate liver/body-weight-ratio, BrdU-proliferation-index (PI), proliferating-cell-nuclear-antigen (PCNA)-mRNA-expression level and autophagy-related-proteins were evaluated. Compared with 90% PVL, additional PHx induced significantly more hypertrophy during the observation time, which was confirmed by significantly higher PI and higher level of PCNA-mRNA expression. Similarly, the additional PHx induced more autophagy in the FLR compared with PVL alone. However, both effects were not clearly related to the extent of additional resection. Additional resection augmented liver regeneration and autophagy substantially compared with PVL alone. Therefore, we concluded that autophagy might play a critical role in regulating hepatocyte proliferation and the size of the FLR after simultaneous PVL + PHx.

Subject terms: Experimental models of disease, Hepatic portal vein, Hepatocytes

Introduction

The liver is the primary site of metastasis for many tumors, especially of colorectal cancer. Surgical resection is the only curative treatment for malignant liver tumors and offers the patients a chance for long-term survival1. At the time of diagnosis, the majority of patients have multiple metastases2. High metastatic burden requires extended liver resection. An important risk of extended liver resection is the inadequate size and function of the FLR, which is associated with substantial postoperative morbidity and mortality3,4. Therefore, patients with a high tumor load are often excluded from this potentially life-saving therapeutic option5.

In the case of initially irresectable liver tumor, different staged procedures were introduced in the clinic: portal vein occlusion followed by PHx, two sequential hepatectomies and the combination of portal vein occlusion and two sequential hepatectomies.

Portal vein occlusion prior to performing the major liver resection is used most frequently to induce hypertrophy of the FLR. Two main technologies were established: portal vein ligation (PVL) and portal vein embolization (PVE)6,7. Portal deprivation causes atrophy of the deportalized liver lobe and compensatory hypertrophy of the portally supplied contralateral lobe. The first successful clinical application of this concept was reported by Makuuchi et al.8, who performed PVE of the tumor-bearing lobe prior to major hepatectomy. They demonstrated that the technique was feasible and decreased the post-hepatectomy liver failure.

Performing portal vein occlusion prior to the major resection broadens the indications of surgical treatment and is now adopted as one standard procedure for patients with initially irresectable tumors. However, around one-third of the patients undergoing portal vein occlusion in the first stage cannot be subjected to the second stage procedure9,10. The most frequently reported reasons are insufficient hypertrophy of the FLR and progression of tumor growth10. Portal vein occlusion prior to major hepatectomy can not only induce hypertrophy in the FLR, but also stimulates tumor growth in both, the occluded lobe and the non-occluded lobe11,12. It was reported that the growth rate of the tumor tissue in the non-ligated liver lobe may even be higher than the growth rate of the healthy non-tumor liver tissue, resulting in persistent irresectability13,14. Thus preoperative portal vein occlusion should not be performed in patients with initially irresectable multiple bilateral colorectal liver metastases.

Another procedure to increase the number of patients eligible for extended surgical resection was introduced by Adam and colleagues, who performed “two-stage (sequential) hepatectomy”2. The procedure consisted of two sequential liver resections to remove initially irresectable multiple bilateral liver tumors (MBLBs). Later, two-sequential hepatectomy was combined with portal vein occlusion15,16. Jaeke et al. reported a small series of successful two-stage hepatectomy combined with PVE in patients with initially irresectable MBLMs. The first-stage hepatectomy cleared all the tumors located in the FLR (the left lobe) and followed by PVE of the right lobe to induce hypertrophy of the FLR. The second-stage major hepatectomy was performed when the hypertrophy of the FLR was sufficient15. Thus the tumor burden was reduced by “cleaning” the FLR completely in the first stage hepatectomy. Using this modified strategy allowed to expand the indications for resecting multiple bilateral colorectal liver metastases and provided selected patients with a chance of a curative treatment. Therefore it is of interest to better understand the effect of combined portal vein occlusion and PHx on intrahepatic size regulation.

In our previous studies17,18, we established a rat model combined PVL and PHx. We investigated the influence of additional PHx on the ligated liver lobe. We found that additional PHx abrogated atrophy and induced mild hepatocyte proliferation in the ligated liver lobe17. Performing a large additional resection (70%PHx) caused a slight increase in the size of the ligated liver lobe which normally undergoes substantial atrophy. However, performing a small additional resection (20%PHx) did not fully prevent atrophy of the ligated liver lobe, but reduced the extent of atrophy substantially compared to PVL alone. Furthermore, we observed an induction of proliferation, down-regulation of apoptosis and an up-regulation of autophagy in the ligated lobe18. In other words, the additional resection had a substantial impact on the size regulation of the ligated lobe, which was related to the extent of the additional resection.

The aim of the present study is to investigate the influence of the additional resection on the size regulation of the non-ligated lobe. We wanted to explore the amount of hypertrophy of the non-ligated FLR after simultaneous PVL and PHx of different extent compared with PVL alone. Furthermore, we wanted to figure out whether the extent of resection itself or the resulting different degree of atrophy in the ligated lobe caused by the different extent of additional liver resection would also affect the extent of hypertrophy in FLR. We were also interested in exploring the role of autophagy in size regulation of the FLR.

We hypothesized that combining PVL and PHx augments the regenerative response in an “extent of resection-dependent” manner compared to PVL alone, possibly facilitated by the induction of autophagy in the FLR.

Results

To investigate this hypothesis we designed a study with three experimental groups: (I) major PVL alone representing the conventional first step in two-stage hepatectomy without atypical resection; (II) major PVL with additional minor liver mass resection, similar to minor “cherry picking” resection; (III) minor PVL with additional major liver mass resection, mimicking a substantial liver resection at the time of portal vein occlusion. The impact of additional liver resection on augmenting the regeneration of the FLR was compared with conventional simple PVL. Furthermore, the effect of performing different extent of additional resection on autophagy in the FLR was evaluated.

Additional PHx did not cause more injury compared to PVL alone

As a first step, we assessed whether the additional resection aggravated the damage to the liver compared with extended PVL. We evaluated the postoperative liver enzyme release. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were selected as markers of acute liver injury following surgical treatment. As partly reported in our previous study17,18, additional PHx did not induce significantly more injury to the liver compared with 90% extended PVL. The level of serum ALT and AST peaked on postoperative day (POD) 1 and decreased progressively to normal level on POD7. No significant differences were observed in the level of AST and ALT after additional PHx and 90%PVL alone (Fig. 1).

Figure 1.

Figure 1

Open in a new tab

Serum level of ALT and AST from serum sample after simultaneous PVL + PHx and PVL alone. To evaluate the surgical stress and liver injury, the level of serum ALT and AST was measured. The serum ALT and AST were increased rapidly after simultaneous PVL + PHx and PVL alone and decreased to normal level within 7 days. No significant difference was observed between simultaneous PVL + PHx and PVL alone.

Additional PHx induced more hypertrophy in the FLR compared with 90%PVL alone

Second, we assessed the hypertrophy of the FLR. To determine the extent of hypertrophy of the non-ligated liver lobe, the caudate lobe to body weight ratio was calculated. At all observation time points, the caudate liver lobe to body weight ratio in the non-ligated remnant liver was significantly higher after simultaneous PVL and PHx compared to PVL alone as shown in Fig. 2 (p < 0.05). On POD2, the caudate liver lobe to body weight ratio after additional large resection was even about twofold higher than after PVL alone. However, no significant difference in the size of the caudated lobe (FLR) was observed when comparing large and small additional resection.

Figure 2.

Figure 2

Open in a new tab

Liver weight to body weght ratio after simultaneous PVL + PHx and PVL alone. The liver/body weight ratio increased steadily after operation. The ratio was significantly higher after additional PHx compared with PVL alone (*p value < 0.05, #p value < 0.01).

Additional PHx induced more hepatocyte proliferation in the FLR than PVL alone

Third, we studied hepatocyte proliferation. Hepatocyte proliferation rate in the FLR was significantly higher on POD2 and 3 after simultaneous PVL and PHx compared with 90%PVL without resection. As shown in Fig. 3a, hepatocyte proliferation in FLR on POD2 increased to 15% and 12% after 20%PVL + 70%PHx respectively 70%PVL + 20%PHx, which were significantly higher compared to 90%PVL alone (Fig. 3b). However, there was no statistically significant difference in hepatocyte proliferation rate when comparing small and large additional liver resection.

Figure 3.

Figure 3

Open in a new tab

BrdU-staining, hepatocyte proliferation index (PI), PCNA mRNA expression level of the non-ligated FLR. (a) Immunohistochemistcal analysis of BrdU incorporation of non-ligated FLR on POD2. More BrdU-positive cells were observed after simultaneous PVL and PHx compared with PVL alone (Scale marker: 100 μm, magnification: ×200). (b) Proliferation index (PI) in the non-ligated FLR was significantly higher on POD2 after additional large PHx and additional small PHx compared with PVL alone (PI: 15% vs 6%, 12% vs 6%, *p value < 0.05). (c) PCNA mRNA expression level in the FLR was substantially increased after additional PHx compared with PVL alone (fold change: 11 vs 8.4 vs 6.7, *p < 0.05).

For further confirmation we assessed PCNA mRNA expression. Here, we observed a significantly higher expression level of PCNA mRNA in the FLR on POD1 after additional large resection compared with the additional small resection and with PVL alone (fold change 11 vs 8.4 vs 6.7, *p < 0.05, Fig. 3c). This effect was not seen on POD2 and 3, where PCNA expression levels in all three groups were about threefold higher compared to normal liver tissue.

Autophagy induction was observed after simultaneous PVL and PHx

In the last step, we studied autophagy. LC3 and phosphorylated mTOR (p-mTOR) are well-chracterized markers in scientific community19,20. To investigate the role of autophagy in promoting regeneration after simultaneous PVL and PHx, the expression levels of the autophagy related proteins LC3 and p-mTOR were determined (Fig. 4). In the early phase of liver regeneration, protein level of LC3II in the FLR was substantially higher on POD1 after simultaneous PVL and PHx compared with PVL alone, indicating a more pronounced induction of autophagy. Furthermore, the protein levels of p-mTOR in the FLR were higher after PVL alone compared with combined PVL and PHx. These results indicated that simultaneous PVL and PHx induced more autophagy compared to PVL alone.

Figure 4.

Figure 4

Open in a new tab

Autophagy related protein expression level in the non-ligated FLR after simultaneous PHx and PVL and PVL alone. Expression level of LC3 and mTOR of total liver homogenates of the FLR was investigated. Substantially higher level of LC3II was observed in additional large PHx and additional small PHx compared with PVL alone. The expression level of p-mTOR showed reverse results.

Discussion

For patients with large or multiple malignant liver tumors, extended hepatectomy is the most successful strategy resulting in a rather favourable treatment outcome. However, substantial removal of liver mass also causes pronounced hepatic injury and a high risk of liver failure due to inadequate size of the FLR. Major hepatectomy is only considered to be feasible when the FLR is ≥ 40% for patients with cirrhotic liver and ≥ 30% in those with significant steatosis or fibrosis without cirrhosis. In patients with normal liver, a FLR of at least ≥ 20% is needed to sustain hepatic function after major hepatectomy21.

Therefore staged liver surgery with or without portal vein occlusion was developed. It is well-known that upon various liver injuries and loss of liver mass, the remaining liver has the ability to compensate the loss of hepatic volume and to restore hepatic function22,23. In the past, different strategies were explored to induce regeneration of the FLR (first stage) prior to performing extended liver resection (second stage)24. These different strategies have in common that regeneration of the FLR is promoted by inflicting a controlled damage on the future resected liver lobe, resulting in regeneration of the FLR. The damage must be “strong enough” to induce regeneration but “weak enough” not to compromise hepatic function substantially. However, it is unknown which and how much damage should be inflicted on the liver to promote regeneration of the FLR while maintaining sufficient hepatic function during this critical period of time.

Theoretically various types of damage could serve the purpose as long as the damage is restricted to the future resected liver lobes and has little effect on the FLR. Portal vein occlusion including portal vein embolization and portal vein ligation was first established to improve resectability25. As outlined before, portal vein occlusion induces atrophy in the ligated liver and promotes hypertrophy in FLR, termed as atrophy/hypertrophy complex (AHC)26. The non-ligated liver lobes undergo regeneration to compensate for the loss of hepatic function of the ligated lobes. Restoration of volume and function of the FLR improves the tolerance to the subsequent major hepatectomy performed as second stage operation27. The flaw of the procedure is that the waiting time between the two procedures may cause disease progression before proceeding to the second step.

In order to further enhance the regenerative process of the FLR under experimental conditions, several additional surgical strategies were developed. Besides PVL of given liver lobes, surgical modifications such as two-stage PVL, additional bile duct ligation and additional hepatic vein ligation were introduced in different experimental models (Table 1).

Table 1.

Experimental studies investigating regeneration in non-ligated liver (FLR) after PVL in rat model.

Year Author Animal Surgical treatment Hypertrophy of FLR Regeneration of FLR
Extenta (%) Observation time Parameter Enhanced regeneration Observation time
2008 Sugimoto et al.30 Wistar rats 90%PVL 315% POD7 PCNA +++ POD2
2-stage 90%PVLb 560% POD14 Mitosis +++ POD8
2015 Ren et al.31 SD rats 90%PVL 250% POD7 Ki67 ++ POD3
90%PBLc 310% POD7 +++ POD3
2019 Kawaguchi et al.33 Wistar rats 90%PVL 393% POD7 Ki67 ++ POD1
90%PVL + 30%HVL 777% POD7 +++ POD3
2019 Jia et al.37 SD rats 70%PVL 291% POD7 Cyclin D1 +++ POD2
Open in a new tab

SD rats Sprague–Dawley rats, HVL hepatic vein ligation, + mild increase, ++ moderate increase, +++ substantial increase.

aWeight ratio of the non-ligated liver lobe to pre-operative value.

b2-stage PVL: first stage: 70%PVL, second stage: 20%PVL on POD7.

cPBL: simultaneous portal vein ligation and bile duct ligation.

Two-stage PVL, 70%PVL followed by the second 20%PVL seven days later, was established by Sugimoto et al. This new strategy was proven to induce more hypertrophy in the FLR compared to the conventional one-stage PVL30. Ren et al. performed simultaneous bile duct and portal vein ligation in a rat model. They demonstrated that the simultaneous procedure accelerated the AHC and promoted hepatic proliferation in the FLR compared to PVL alone31. Additional hepatic vein ligation at the time of PVL was introduced by Kawaguchi et al. They found that additional hepatic vein occlusion resulted in more damage in the ligated lobe and induced more regeneration in the non-ligated liver compared with PVL alone33.

In the present study, we suggest not to induce additional damage on the portally deprived liver but to remove part of the liver, as done clinically when “cleaning” the liver from bilobar metastasis. The additional resection serves two purposes: on the one hand to enhance regeneration of the FLR and on the other hand to mimic the clinical situation of “reducing the tumor load” of the liver. Furthermore using our novel model combining different extent of PVL with different extent of PHx, we can study intrahepatic size regulation. In the previous study18, we demonstrated that simultaneous PVL and PHx was a well-tolerated procedure allowing all rats to survive even when reducing the size of the healthy FLR to only 10% of the original liver mass. In the present study, we found that the combined procedure induced more hepatocyte proliferation and faster course of liver hypertrophy in the FLR than after PVL alone. However, we did not see a statistically significant additional effect on size regulation of the FLR when increasing the size of resection.

Using our model of simultaneous PVL and PHx, we observed previously in the ligated lobe that induction of the energy consuming process of hepatocyte proliferation was related to an increase in the energy providing process autophagy18. In the present study, we observed that increased regeneration of the non-ligated lobe after additional resection was also associated with an increased expression of autophagy related proteins.

The relationship between autophagy and liver regeneration is currently discussed in many experimental studies (see Table 2). Recently, experimental evidence is accumulating that autophagy activity plays an essential role in promoting regeneration and reducing organ damage32,34–36. It was reported that augmenter of liver regeneration promoted hepatocyte proliferation in mice through activation of autophagy in CCl4-induced acute liver injury32. In a mouse model with 2/3 hepatectomy, Lu et al. found that miR-1907 accelerated hepatocyte proliferation via activating autophagy. They further observed a significant decrease in miR-1907-induced liver regeneration after inhibiting autophagy36. Activation of autophagy in the non-ligated lobe following 70%PVL was also observed in a rat model. The study suggested that the increased autophagy activity was positively related to rapid hepatocyte proliferation37. Our present study further confirms these observations, since we also found that simultaneous PVL and PHx induced not only more regeneration but also more autophagy in the FLR than PVL alone.

Table 2.

Experimental studies investigating the protective role of autophagy during liver regeneration.

Year Author Experimental model Surgical strategy Pharmacological intervention Autophagy Regeneration
Parameter Observation time Parameter Observation time
2014 Toshima et al.35 Wild-type Atg5 Mice 70%PHx / LC3-II++, P62+ POD1 BrdU+++, Cyclin D+++ POD1
L-Atg5KO micea 70%PHx / LC3-II−−−, P62+++ POD1 BrdU+, Cyclin D− POD1
Hepatocytes / HGFb LC3-II+++ / Cyclin D+++ /
2015 Lin et al.34 C57BL/6 Mice 70%PHx / LC3-II++, P62+ POD1 Ki67++, PCNA++ POD2
Amiodarone LC3-II+++, P62− POD1 Ki67+++, PCNA+++ POD2
Chloroquine LC3-II+++, P62+++ POD1 Ki67+, PCNA− POD2
2016 Shi et al.32 BALB/c mice / CCl4 LC3-II+++, P62+++ POD2 PCNA−−−, CyclinD−−− POD2
CCl4 + ALR LC3-II+++, P62−−− POD2 PCNA+++, Cyclin D+++ POD2
CCl4 + 3-MAc / / PCNA−−−, CyclinD−−− POD2
2018 Lu et al.36 C57BL/6 Mice 70%PHx miR-1907 LC3-II+++, P62−−− POD2 BrdU+++, PCNA+++ POD2
2019 Jia et al.37 SD rats 70%PVL / LC3-II+++ POD1 Cyclin D+++ POD1
2019 Matsumoto et al.39 C57BL/KsJ m + /m + mice(control) 70%PHx / LC3-II+++, P62- POD1 PCNA+++, Cyclin D+++ POD2
C57BL/KsJ db/db miced 70%PHx / LC3-II+++, P62+++ POD1 PCNA+, Cyclin D− POD2
Open in a new tab

aAtg5-deficient mice.

bHepatocyte growth factor.

c3-MA: 3-Methyladenine, autophagy inhibitor.

dModel of liver steatosis and diabetes.

Based on these recent studies about the critical role of autophagy in liver regeneration, we suggest that the process of regeneration in the FLR after simultaneous PHx and PVL or PVL alone might also be further augmented by applying autophagy inducers. Application of an mTOR-independent autophagy promoter in an animal model of PVL or simultaneous PVL and PHx seems to be an interesting approach to be investigated. This strategy might induce more proliferation and augment hypertrophy of the FLR more than PVL alone, thereby shortening the interval time needed for restoring the original liver mass.

In summary, better understanding of the interaction between liver regeneration and autophagy after PVL and PHx is useful to refine therapeutic strategies for patients with primarily irresectable liver disease. Additional PHx will not only promote regeneration of the FLR but also reduce the tumor load in the first step, thereby preventing the increase of tumor burden during the waiting period.

Conclusion

Simultaneous PVL and PHx procedures were performed on healthy rats without malignant disease resulting in augmented regeneration of the FLR and an enhancement of autophagy. These observations call for further exploration of promoting autophagy as novel strategy to augment liver regeneration in this complex surgical model.

Methods

Animals

Male Lewis rats weighing 250–300 g (9–10 weeks old), purchased from Charles River, Sulzfeld, Germany, were used in the present study. The rats were housed under constant room temperature and humidity and a 12 h-light–dark cycle in a conventional animal facility. Water and rat chow were provided ad libitum.

Ethics statement

The protocols were approved by the Thüringer Landesamt für Verbraucherschutz, Thuringia, Germany (Approval-Number: 02-024/13). All experiments and housing of animals were performed in compliance with the current German regulations and guidelines for animal welfare and the ARRIVE Guidelines for Reporting Animal Research28.

Experimental design

Male Lewis rats were assigned into two experimental groups (Fig. 5): 20%PVL + 70%PHx: ligation of right portal vein (20% of the liver mass) followed by resection of left lateral and median lobes (70% of the liver mass); 70%PVL + 20%PHx: ligation of right and left portal vein followed resection of right lobe. The control consisted of additional twenty-four rats subjected to 90% PVL group which underwent ligation of left lateral, median and right lobes portal vein. Animals were observed for 24 h, 48 h, 72 h and 7 days postoperatively (n = 6/observation time point).

Figure 5.

Figure 5

Open in a new tab

Sketches of experimental groups. LLL left lateral lobe, ML median lobe, RL right lobe, CL caudate lobe, PV portal vein; liver lobe with grey color: ligated lobe, liver lobe with orange color: non-ligated FLR, red cross: portal vein ligation.

Operative procedures and postoperative management

The rats were acclimatized for 1 week before operation. Surgical procedures were conducted under inhalation anesthesia consisting of a mixture of 3% isoflurane and pure oxygen at a flow rate of 0.5 L/min (isoflurane vaporizer, Sigma Delta, UK). Following skin disinfection, the abdominal cavity was opened via a transverse upper abdominal incision. The intestine was eventerated and covered by wet gauze. Portal vein branches were dissected from artery and bile duct and then ligated with 6–0 prolene suture using an operating microscope (Zeiss, magnification 10–25×, Germany). Ligation of right portal vein represented 20%PVL, ligation of left portal vein represented 70%PVL, and ligation of both right and left portal vein represented 90%PVL. Additional PHx was then performed as described previously17. A Mosquito-clamp was placed on each liver lobe 2–3 mm distal from the inferior vena cava. The clamp was kept stable while removing the liver lobe and placing 2–4 piercing sutures. Next, the clamp was removed followed by replacing the abdominal viscera and closing abdomen. A dose of 0.05 mg/kg body weight of buprenorphine was applied as analgesic treatment to all animals postoperatively (Temgesic, Essex Pharma GmbH, Germany). Daily evaluation of general condition and activity was carried out after operation.

Harvesting and sampling

Rats were sacrificed postoperatively day 1, 2, 3 and 7. For detecting hepatocyte proliferation in the FLR, rats were injected intravenously with a single dose of 50 mg/kg 5-bromo-2-deoxyuridine (BrdU, SIGMA-ALDRICH, St. Louis, USA) one hour before sacrifice.

Blood collection was performed under anesthesia and liver tissue was harvested. The wet weight of remnant liver was measured and the liver weight/body weight ratio was calculated using the following formula: individual liver lobe weight (g)/body weight (g) × 100%.

Serum was isolated from the blood. The serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured by using the AEROSET System (Abbott Laboratories, Wiesbaden, Germany).

Histology and immunohistochemistry (IHC) analysis

Liver tissue was fixed by immersion in 4.5% buffered formalin for 48 h and embedded in paraffin. Paraffin sections of 4 µm thickness were prepared. BrdU-staining was performed for visualization of hepatocyte proliferation. A monoclonal anti-BrdU antibody (Dako, Hamburg, Germany) was use in the staining, following the protocol described previously17. Immunohistochemistry results were analyzed with the Histokat software (Fraunhofer MEVIS, Bremen, Germany) using a nuclei detection algorithm based on a previously published image analysis method17. The algorithm used machine learning techniques to recognize BrdU-positive and BrdU-negative nuclei, taking into account color, roundness and size features. The proliferation index was calculated as the fraction of the amount of BrdU-positive nuclei to the total number of hepatocyte nuclei, according to previously reported protocol.

Protein extraction and Western blotting

Liver tissues were homogenized in the RIPA buffer (sigma, R0278) containing the Protease and phosphatase inhibitor cocktail (Thermo Scientific, USA). The concentration of total proteins was measured by using BCA protein assay kit (Thermo Scientific, USA) and ELISA reader device. Equal amounts of protein were denatured with Laemmli sample buffer (Bio-Rad, USA). Proteins were separated in electrophoresis process and transferred to the polyvinylidene difluoride membranes. The membranes were washed and blocked as previously reported38. The blots were cut prior to hybridization with primary antibodies. Primary antibodies rabbit anti-light chain 3 (LC3; 1:1000, Cell signaling Technology), rabbit anti-mammalian target of rapamycin (mTOR, 1:1000,Cell signaling Technology), rabbit anti-phospho-mTOR (Ser2448, 1:1000, Cell signaling Technology) and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:10,000, Cell signaling Technology) were applied to the membranes and were incubated at 4 °C overnight. After the membranes being washed, the second antibody (Goat polyclonal antibody to rabbit IgG; 1:5000) was then used. After being probed by using enhanced chemiluminescence western blotting substrate (GE Healthcare), the signals were visualized by using Fusion FX7 (Labtech International Ltd, Heathfield, United Kingdom). All western blots were repeated 3 times (Supplementary Information).

Real time PCR analysis

Total RNA was isolated from liver tissue sections using the RNeasy kit (Qiagen, Hilden, Germany) following the manufacture’s instruction. RNA samples were reverse transcribed to cDNA by using the First-Strand cDNA synthesis KIT (Invitrogen, Carlsbad, USA). The mRNA expression of PCNA was investigated using the Brilliant probe-based QPCR Mater Mix kit (Agilent, Santa Clara, USA), performed by using M3000P QPCR System (Stratagene, La Jolla, USA). The mRNA level of HPRT was served as an endogenous control. The primers (eurofins Genomics, Germany) were listed as following: proliferating cell nuclear antigen (PCNA):forward5′-TGAACTTTTTCACAAAAGCCACT-3′, reverse5′TGTCCCATGTCAGCAATTTTA-3′; hypoxanthine guanine phosphoribosyltransferase (HPRT): forward5′-GACCGGTTCTGTCATGTCG-3′, reverse5′-ACCTGGTTCATCATCACTAATCAC-3′. Relative fold of gene expression of samples was calculated by the well-accepted 2–∆∆Ct method.

Statistical analysis

SigmaPlot 13.0 (Statcon, Witzenhausen, Germany) was adopted for data analysis. The differences between groups were compared using the one way independent ANOVA test. Statistical differences were considered significant when p values were less than 0.05.

Supplementary Information

Supplementary Information. (202.2KB, pdf)

Acknowledgements

The work was supported by grants from German Federal Ministry of Education and Research (BMBF) via the systems biology network “Virtual Liver” (VLN-BMBF: 0315765).

Abbreviations

PHx

Partial hepatectomy

PVL

Portal vein ligation

PVE

Portal vein embolization

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

BrdU

5-Bromo-2-deoxyuridine

PI

Proliferation index

POD

Postoperative day

PCNA

Proliferating cell nuclear antigen

Author contributions

C.H. and W.W. performed the experiments and drafted the manuscript. T.Z. helped in data acquisition and manuscript revision. F.X. took part in the manuscript revision. A.H. supported the image analysis. O.D. and U.D. supported the development of the experimental design and revised this manuscript. U.S. was involved in critical discussion of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

All data generated or analyzed during this study are included in this presented article. Parts of the data in this manuscript were presented in our previous paper18 and Dr. Wei’s thesis. (https://www.dbthueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00039437/disswei.pdf).

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Chuanfeng Hua and Weiwei Wei.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-90819-x.

References

  • 1.Geng L, Zong R, Shi Y, Xu K. Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2020;32:769–778. doi: 10.1097/MEG.0000000000001618. [DOI] [PubMed] [Google Scholar]
  • 2.Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann. Surg. 2000;232:777–785. doi: 10.1097/00000658-200012000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Isfordink CJ, et al. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: A systematic review and meta-analysis. Surg. Oncol. 2017;26:257–267. doi: 10.1016/j.suronc.2017.05.001. [DOI] [PubMed] [Google Scholar]
  • 4.Garcea G, Ong SL, Maddern GJ. Predicting liver failure following major hepatectomy. Dig. Liver Dis. 2009;41:798–806. doi: 10.1016/j.dld.2009.01.015. [DOI] [PubMed] [Google Scholar]
  • 5.Riddiough GE, Christophi C, Jones RM, Muralidharan V, Perini MV. A systematic review of small for size syndrome after major hepatectomy and liver transplantation. HPB (Oxford) 2020;22:487–496. doi: 10.1016/j.hpb.2019.10.2445. [DOI] [PubMed] [Google Scholar]
  • 6.Rous P, Larimore LD. Relation of the portal blood to liver maintenance: A demonstration of liver atrophy conditional on compensation. J. Exp. Med. 1920;31:609–632. doi: 10.1084/jem.31.5.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.van Gulik TM, van den Esschert JW. James Cantlie's early messages for hepatic surgeons: How the concept of pre-operative portal vein occlusion was defined. HPB (Oxford) 2010;12:81–83. doi: 10.1111/j.1477-2574.2009.00124.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Makuuchi M, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report. Surgery. 1990;107:521–527. [PubMed] [Google Scholar]
  • 9.Garcia-Perez R, et al. Associated liver partition and portal vein ligation (ALPPS) vs selective portal vein ligation (PVL) for staged hepatectomy in a rat model. Similar regenerative response? PLoS One. 2015;10:e0144096. doi: 10.1371/journal.pone.0144096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J. Surg. Oncol. 2010;102:960–967. doi: 10.1002/jso.21654. [DOI] [PubMed] [Google Scholar]
  • 11.Kokudo N, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology (Baltimore, MD) 2001;34:267–272. doi: 10.1053/jhep.2001.26513. [DOI] [PubMed] [Google Scholar]
  • 12.Hoekstra LT, et al. Tumor progression after preoperative portal vein embolization. Ann. Surg. 2012;256:812–817. doi: 10.1097/SLA.0b013e3182733f09. [DOI] [PubMed] [Google Scholar]
  • 13.Elias D, et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br. J. Surg. 1999;86:784–788. doi: 10.1046/j.1365-2168.1999.01154.x. [DOI] [PubMed] [Google Scholar]
  • 14.Bretagnol F, et al. Selective portal vein embolization and colorectal liver metastases in rat: A new experimental model for tumor growth study. J. Surg. Res. 2011;171:669–674. doi: 10.1016/j.jss.2010.03.047. [DOI] [PubMed] [Google Scholar]
  • 15.Jaeck D, et al. One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am. J. Surg. 2003;185:221–229. doi: 10.1016/s0002-9610(02)01373-9. [DOI] [PubMed] [Google Scholar]
  • 16.Narita M, et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br. J. Surg. 2011;98:1463–1475. doi: 10.1002/bjs.7580. [DOI] [PubMed] [Google Scholar]
  • 17.Wei W, et al. Intrahepatic size regulation in a surgical model: Liver resection-induced liver regeneration counteracts the local atrophy following simultaneous portal vein ligation. Eur. Surg. Res. 2016;57:125–137. doi: 10.1159/000446875. [DOI] [PubMed] [Google Scholar]
  • 18.Wei W, et al. Size of portally deprived liver lobe after portal vein ligation and additional partial hepatectomy: Result of balancing proliferation and apoptosis. Sci. Rep. 2020;10:4893. doi: 10.1038/s41598-020-60310-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gomez-Sanchez R, et al. Routine Western blot to check autophagic flux: Cautions and recommendations. Anal. Biochem. 2015;477:13–20. doi: 10.1016/j.ab.2015.02.020. [DOI] [PubMed] [Google Scholar]
  • 20.Li MY, et al. Adrenomedullin alleviates the pyroptosis of Leydig cells by promoting autophagy via the ROS-AMPK-mTOR axis. Cell Death Dis. 2019;10:489. doi: 10.1038/s41419-019-1728-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Khan AS, et al. Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review. Int. J. Surg. 2018;52:74–81. doi: 10.1016/j.ijsu.2018.01.042. [DOI] [PubMed] [Google Scholar]
  • 22.Yamanaka N, et al. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology (Baltimore, MD) 1993;18:79–85. doi: 10.1002/hep.1840180114. [DOI] [PubMed] [Google Scholar]
  • 23.Ibis C, et al. Factors affecting liver regeneration in living donors after hepatectomy. Med. Sci. Monit. 2017;23:5986–5993. doi: 10.12659/msm.908136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Szijarto A, Fulop A. Triggered liver regeneration: From experimental model to clinical implications. Eur. Surg. Res. 2015;54:148–161. doi: 10.1159/000368961. [DOI] [PubMed] [Google Scholar]
  • 25.Tustumi F, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: A systematic review and meta-analysis. HPB (Oxford) 2018;20:1109–1118. doi: 10.1016/j.hpb.2018.06.1798. [DOI] [PubMed] [Google Scholar]
  • 26.Kovacs T, et al. Functional shift with maintained regenerative potential following portal vein ligation. Sci. Rep. 2017;7:18065. doi: 10.1038/s41598-017-18309-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Nagano Y, et al. Improved functional reserve of hypertrophied contra lateral liver after portal vein ligation in rats. J. Hepatol. 2002;37:72–77. doi: 10.1016/s0168-8278(02)00088-0. [DOI] [PubMed] [Google Scholar]
  • 28.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412. doi: 10.1371/journal.pbio.1000412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Autophagy. 2016;12:1–222. doi: 10.1080/15548627.2015.1100356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sugimoto T, et al. Two-stage portal vein ligation facilitates liver regeneration in rats. Eur. Surg. Res. 2009;42:181–188. doi: 10.1159/000203406. [DOI] [PubMed] [Google Scholar]
  • 31.Ren W, et al. Simultaneous bile duct and portal vein ligation induces faster atrophy/hypertrophy complex than portal vein ligation: Role of bile acids. Sci. Rep. 2015;5:8455. doi: 10.1038/srep08455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shi H, et al. Augmenter of liver regeneration protects against carbon tetrachloride-induced liver injury by promoting autophagy in mice. Oncotarget. 2017;8:12637–12648. doi: 10.18632/oncotarget.14478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kawaguchi D, et al. Effect of portal vein ligation plus venous congestion on liver regeneration in rats. Ann. Hepatol. 2019;18:89–100. doi: 10.5604/01.3001.0012.7866. [DOI] [PubMed] [Google Scholar]
  • 34.Lin CW, et al. Amiodarone as an autophagy promoter reduces liver injury and enhances liver regeneration and survival in mice after partial hepatectomy. Sci. Rep. 2015;5:15807. doi: 10.1038/srep15807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Toshima T, et al. Suppression of autophagy during liver regeneration impairs energy charge and hepatocyte senescence in mice. Hepatology (Baltimore, MD) 2014;60:290–300. doi: 10.1002/hep.27140. [DOI] [PubMed] [Google Scholar]
  • 36.Lu T, et al. Partial hepatectomy-induced upregulation of miR-1907 accelerates liver regeneration by activation autophagy. Biomed. Res. Int. 2018;2018:3817057. doi: 10.1155/2018/3817057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jia CJ, Sun H, Dai CL. Autophagy contributes to liver regeneration after portal vein ligation in rats. Med. Sci. Monit. 2019;25:5674–5682. doi: 10.12659/MSM.915404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Liu A, Fang H, Dahmen U, Dirsch O. Chronic lithium treatment protects against liver ischemia/reperfusion injury in rats. Liver Transpl. 2013;19:762–772. doi: 10.1002/lt.23666. [DOI] [PubMed] [Google Scholar]
  • 39.Matsumoto Y, et al. Ectopic localization of autophagosome in fatty liver is a key factor for liver regeneration. Organogenesis. 2019;15:24–34. doi: 10.1080/15476278.2019.1633872. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information. (202.2KB, pdf)

Data Availability Statement

All data generated or analyzed during this study are included in this presented article. Parts of the data in this manuscript were presented in our previous paper18 and Dr. Wei’s thesis. (https://www.dbthueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00039437/disswei.pdf).

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES